Wall Street brokerages expect that Amicus Therapeutics, Inc. (NASDAQ:FOLD) will announce sales of $9.93 million for the current quarter, according to Zacks. Three analysts have provided estimates for Amicus Therapeutics’ earnings. The highest sales estimate is $10.08 million and the lowest is $9.76 million. Amicus Therapeutics reported sales of $2.13 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 366.2%. The company is scheduled to issue its next quarterly earnings results on Monday, November 6th.
According to Zacks, analysts expect that Amicus Therapeutics will report full-year sales of $9.93 million for the current fiscal year, with estimates ranging from $32.90 million to $37.13 million. For the next year, analysts expect that the company will report sales of $93.45 million per share, with estimates ranging from $69.78 million to $115.84 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Amicus Therapeutics.
Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. The firm had revenue of $7.16 million for the quarter, compared to analysts’ expectations of $6.96 million. During the same quarter in the previous year, the company earned ($0.40) earnings per share.
Several analysts have recently commented on the stock. Zacks Investment Research raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. BidaskClub raised shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th. Robert W. Baird increased their price target on shares of Amicus Therapeutics from $12.00 to $15.00 and gave the company an “outperform” rating in a research note on Wednesday, July 12th. J P Morgan Chase & Co reissued an “overweight” rating and set a $15.00 price target (up from $13.00) on shares of Amicus Therapeutics in a research note on Wednesday, August 9th. Finally, Chardan Capital increased their price target on shares of Amicus Therapeutics from $12.50 to $17.50 and gave the company a “buy” rating in a research note on Thursday, August 10th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $14.58.
In other Amicus Therapeutics news, major shareholder Life Sciences Maste Perceptive acquired 1,500,000 shares of Amicus Therapeutics stock in a transaction on Thursday, July 13th. The shares were purchased at an average cost of $12.25 per share, with a total value of $18,375,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jay Barth sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $10.00, for a total transaction of $300,000.00. Following the completion of the transaction, the insider now directly owns 64,184 shares in the company, valued at $641,840. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by company insiders.
A number of hedge funds have recently made changes to their positions in FOLD. Teachers Advisors LLC boosted its stake in Amicus Therapeutics by 18.6% in the fourth quarter. Teachers Advisors LLC now owns 240,563 shares of the biopharmaceutical company’s stock valued at $1,196,000 after acquiring an additional 37,705 shares during the last quarter. Nationwide Fund Advisors raised its holdings in Amicus Therapeutics by 11.5% in the first quarter. Nationwide Fund Advisors now owns 131,945 shares of the biopharmaceutical company’s stock worth $941,000 after purchasing an additional 13,563 shares during the period. Russell Investments Group Ltd. raised its holdings in Amicus Therapeutics by 1,004.9% in the first quarter. Russell Investments Group Ltd. now owns 121,338 shares of the biopharmaceutical company’s stock worth $865,000 after purchasing an additional 110,356 shares during the period. Wells Fargo & Company MN raised its holdings in Amicus Therapeutics by 51.7% in the first quarter. Wells Fargo & Company MN now owns 153,473 shares of the biopharmaceutical company’s stock worth $1,094,000 after purchasing an additional 52,287 shares during the period. Finally, Princeton Alpha Management LP acquired a new stake in Amicus Therapeutics in the first quarter worth $106,000.
ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Anticipate Amicus Therapeutics, Inc. (FOLD) Will Announce Quarterly Sales of $9.93 Million” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/2888076/zacks-brokerages-anticipate-amicus-therapeutics-inc-fold-will-announce-quarterly-sales-of-9-93-million.html.
Shares of Amicus Therapeutics (NASDAQ FOLD) opened at 13.28 on Wednesday. The company’s market cap is $2.19 billion. The company’s 50-day moving average price is $13.21 and its 200 day moving average price is $9.61. Amicus Therapeutics has a one year low of $4.41 and a one year high of $14.36.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.